> See specialized channels
Medical Devices & Diagnostics
> See specialized channels
> See specialized channels

  Join us

  Follow us on Twitter   Join our LinkedIn Group   Our Blog

Biotech News App
Provides access to the latest biotech press releases ...more

Android_Logo App Store RIM_Logo_small

Media Partnership:
Want to have your RSS feed integrated on our website? Contact us
RSS Feeds RSS Feeds
JoomlaWatch Stats 1.2.9 by Matej Koval
For Editors
Sign up for press releases
For Companies
Sign up for our newsletter

Probiogen Signs Therapeutic Protein Process Development Contract With Virdante Pharmaceuticals

| Print |
Wednesday, 28 April 2010 10:00 (UTC + 2)


Berlin, Germany, April 28th, 2010 / b3c newswire /- ProBioGen AG (“ProBioGen”), a technology and service provider for the development and production of biopharmaceutical drug substances today announced signing a contract with Virdante Biopharmaceuticals, Inc., a US-based biopharmaceutical development company (“Virdante”).


ProBioGen will contribute producer cell line development and process engineering for one of Virdante’s proprietary therapeutic proteins. Virdante’s protein products are unique in that they incorporate the company’s proprietary “Sialic Switch” technology that improves the anti-inflammatory properties of an antibody for autoimmune and inflammatory diseases. Virdante selected ProBioGen for its expertise in developing royalty-free pharmaceutical cell lines and robust, economical processes for GMP-manufacturing.


“We are highly impressed by Virdante´s products and strategies and their compelling scientific rationale to improve human proteins. We are excited to contribute our knowledge in harnessing the cellular machinery to maximize productivity for this ambitious project“, commented Dr. Volker Sandig, Chief Scientific Officer of ProBioGen.


About ProBioGen - www.probiogen.de
ProBioGen is a technology and service provider that supports and adds value to its clients’ biopharmaceutical drug development. A proven track record of fee-for-service-based projects, from cell line development, over process engineering, up to GMP manufacturing is strengthened by novel expression systems and unique analytical testing services.

In addition to its CHO platform, ProBioGen has developed proprietary AGE1® producer cell lines, for safe and cost-efficient production of highly active glycoproteins, monoclonal antibodies and virus-based vaccines. ProBioGen employs a broad range of qualified cell-based assays and a services and technologies are embedded in a total quality management system, compliant with international ISO and GMP standards. ProBioGen was founded in 1994 and is located in Berlin, Germany.


About Virdante - www.virdante.com
Virdante Pharmaceuticals is developing safer and more effective drugs for autoimmune and inflammatory diseases. Our products incorporate a proprietary “Sialic Switch” technology to improve the anti-inflammatory properties of antibodies. Virdante is located in Cambridge, MA.



Contact for ProBioGen:

Dr Gertraud Unterrainer, CFO
Goethestrasse 54
13086 Berlin
Tel.: +49 (0)30 924 006-0
Fax: +49 (0)30 924 006-19
email: This e-mail address is being protected from spambots. You need JavaScript enabled to view it